Dr. Mellinghoff is Chair of the Department of Neurology and incumbent of the Evnin Family Chair in Neuro-Oncology at Memorial Sloan Kettering Cancer Center. Dr. Mellinghoff contributed fundamental insights into aberrant signal transduction in primary brain tumors, including growth factor receptor signaling in glioblastoma, isocitrate dehydrogenase in low-grade glioma, and Bruton's Tyrosine Kinase in CNS Lymphoma. He also led clinical trials with investigational agents targeting these pathways.